Friday, July 10, 2026

Drug profile · INN

leuprorelin

leuprorelin (ELIGARD 1 MONTH) is an FDA-listed pharmaceutical active ingredient. Associated with AbbVie.

EMA: approved TGA: approved
Patents linked 0
Pipeline programs 39
News articles 0
Drug details — leuprorelin

Quick answer

leuprorelin (ELIGARD 1 MONTH) is an FDA-listed pharmaceutical active ingredient. Associated with AbbVie.

Key facts

INN leuprorelin
Brand ELIGARD 1 MONTH
Originator AbbVie

Approval history

Authority Status Date
EMA approved
TGA approved

Pipeline programs

  1. 1414-ROG-GUCG Phase 3 · Ningbo Cancer Hospital · very high risk localized or locally advanced prostate cancer
  2. 5mg Serlopitant Tablets Phase 3 · VYNE Therapeutics · Pruritus
  3. 6-month course of antiandrogen drugs Phase 3 · First People's Hospital · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  4. CAAA617C12301 Phase 3 · Novartis India · PSMA-positive metastatic hormone-sensitive prostate cancer (
  5. CLEE011O12001 Phase 3 · Novartis India · HR-positive HER-2- negative Breast Cancer
  6. CO44657 Phase 3 · HOFFMANN-LA ROCHE · Estrogen receptor (ER)-positive, HER2-negative advanced brea
  7. D8532C00001 Phase 3 · AstraZeneca · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Ca
  8. D8534C00001 Phase 3 · AstraZeneca · Estrogen Receptor-Positive, HER-2 negative Advanced Breast C

Frequently asked questions

What is leuprorelin?

leuprorelin (ELIGARD 1 MONTH) is an FDA-listed pharmaceutical active ingredient. Associated with AbbVie.

What is the brand name for leuprorelin?

ELIGARD 1 MONTH is a marketed brand name for leuprorelin. Check FDA Drugs@FDA for the current US label holder and prescribing information.